Galecto Inc

NASDAQ:GLTOUnited States

Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Contact Information

Headquarters

75 State Street, Suite 100BOSTON, MA, United States 02109

Phone

---

Fax

302-655-5049

Executives

Independent Chairman of the Board

Carl Goldfischer

President, Chief Executive Officer, Director

Hans Schambye

Chief Financial Officer

Jonathan Freve

Chief Operating Officer

Anders Pedersen

General Counsel, Corporate Secretary

Garrett Winslow